Bioceres Crop Solutions Corp.BIOX
| Jun 30,
2019 | Jun 30,
2020 | Jun 30,
2021 | Jun 30,
2022 | Jun 30,
2023 | Jun 30,
2024 |
|---|
| Result for the year | -16,358,891 | 4 | -3,820,622 | -3,908,904 | 20 | 6 |
|---|
| Income tax | 7 | 2 | 14 | 18 | -1,068,652 | 4 |
|---|
| Financial results | 41 | 33 | 28 | 26 | 35 | 35 |
|---|
| Adjustments for depreciation expense | 2 | 2 | 3 | 4 | 5 | 6 |
|---|
| Amortization of intangible assets | 2 | 2 | 2 | 4 | 11 | 12 |
|---|
| Depreciation of leased assets | - | 566,818 | 827,320 | 1 | 4 | 3 |
|---|
| Transactional expenses | 5 | - | 2 | 971,539 | 4 | 1 |
|---|
| Adjustments for share-based payments | - | 3 | 2 | 1 | 3 | 14 |
|---|
| Share of profit or loss of joint ventures and associates | 1 | 2 | 997,429 | 1 | 1 | 4 |
|---|
| Loss of participation in joint ventures and associates | - | - | - | - | -133,079 | - |
|---|
| Adjustments for provisions | -246,832 | 200,525 | 158,818 | 292,732 | 221,008 | 367,126 |
|---|
| Allowance for impairment of trade debtors | 686,985 | 1 | 560,931 | 2 | 1 | 753,428 |
|---|
| Allowance for obsolescence | 564,873 | 977,817 | 579,832 | 849,641 | 1 | 586,515 |
|---|
| Initial recognition and changes in the fair value of biological assets | - | -716,741 | -2,826,255 | -6,388,030 | -610,554 | 45,746 |
|---|
| Changes in the net realizable value of agricultural products after harvest | - | - | - | -42,523 | -4,351,433 | -2,385,069 |
|---|
| Gain on sale of equipment and intangible assets | 91,762 | 297,289 | 733,042 | -1,944,308 | -74,593 | -125,464 |
|---|
| Trade receivables | 41 | -23,022,695 | 2 | -24,971,064 | -56,867,123 | -46,681,153 |
|---|
| Other receivables | 6 | -4,827,495 | -8,330,278 | -7,298,822 | -11,475,717 | -4,967,150 |
|---|
| Income and minimum presumed income taxes | 3 | 1 | 6 | 6 | -16,154,083 | 5 |
|---|
| Inventories and biological assets | - | - | 35 | 55 | 11 | -14,176,656 |
|---|
| Trade and other payables | -33,699,077 | 8 | -5,831,743 | 53 | -4,501,398 | 14 |
|---|
| Employee benefits and social security | 931,656 | -474,220 | -693,125 | 3 | 1 | -2,289,095 |
|---|
| Deferred revenue and advances from customers | 66,178 | 864,905 | 2 | -373,584 | 13 | -21,087,704 |
|---|
| Income taxes paid | -1,705,481 | - | -1,837,775 | -7,059,177 | -4,072,347 | -853,299 |
|---|
| Government grants | -23,019 | -6,603 | -2,821 | -784 | - | - |
|---|
| Interest collected | - | 1 | 3 | 6 | 5 | 3 |
|---|
| Inflation effects on working capital adjustments | -18,411,538 | -13,663,552 | -14,735,250 | -35,846,973 | 376,597 | 321,103 |
|---|
| Net cash flows generated / (used) by operating activities | 30 | 11 | -6,205,943 | -17,515,374 | 3 | 42 |
|---|
| Proceeds from sale of property, plant and equipment | 317,953 | 51,151 | 309,810 | 2 | 137,357 | 336,726 |
|---|
| Net cash received from business combination | - | - | 355,804 | - | 4 | 37,508 |
|---|
| Net loans granted to shareholders and other related parties | - | - | - | 421,691 | - | - |
|---|
| Proceeds from financial assets | - | - | - | - | 1 | 888,140 |
|---|
| Investment in financial assets | - | - | - | - | - | 7 |
|---|
| Purchase of property, plant and equipment | 2 | 2 | 3 | 3 | 11 | 10 |
|---|
| Capitalized development expenditures | 682,530 | 1 | 4 | 5 | 11 | 12 |
|---|
| Purchase of intangible assets | 722,833 | 2 | 7 | 389,039 | 449,673 | 1 |
|---|
| Net cash flows (used) /generated by investing activities | -3,260,852 | -22,212,249 | -8,310,118 | 3 | -25,725,670 | -28,728,255 |
|---|
| Proceeds from borrowings | 89 | 135 | 143 | 140 | 80 | 136 |
|---|
| Repayment of borrowings and financed payments | 111 | 101 | 126 | 124 | 17 | 113 |
|---|
| Interest payments | - | - | - | - | 18 | 25 |
|---|
| Decrease in bank overdrafts and other short-term borrowings | -4,968,813 | -2,331,974 | -3,442,491 | -32,838 | - | - |
|---|
| Other financial payments | -854,731 | 2 | -1,415,034 | -180,538 | -4,767,378 | -2,746,945 |
|---|
| Acquisition of non-controlling interest in subsidiaries | - | - | - | 724,429 | - | - |
|---|
| Purchase of own shares | - | 30,906 | 4 | - | 3 | 734,388 |
|---|
| Leased assets payments | - | 433,947 | 728,964 | 1 | 4 | 5 |
|---|
| Cash dividend distributed by subsidiary | - | - | - | - | 452,129 | 174,800 |
|---|
| Net cash flows (used) /generated by financing activities | -26,946,194 | 34 | 7 | 15 | 33 | -10,055,867 |
|---|
| Net increase in cash and cash equivalents | -512,233 | 23 | -7,157,932 | 211,214 | 10 | 3 |
|---|
| Inflation effects on cash and cash equivalents | 2 | -552,459 | -5,584,156 | -9,624,750 | -101,767 | -31,918 |
|---|
| Effect of exchange rate changes on cash and equivalents | 66,890 | 2 | 6 | 7 | 5 | -6,556,470 |
|---|